Frontline Treatment of Acute Myeloid Leukemia : Episode 8
Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine
Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.
Recent Videos
Related Content
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
November 12th 2024Article
In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.
Read More
Uproleselan With Chemo Fails to Improve EFS in Older Patients With AML
November 2nd 2024Article
A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.
Read More
